0.4719
Evoke Pharma Inc stock is currently priced at $0.4719, with a 24-hour trading volume of 26,288.
It has seen a -10.13% decreased in the last 24 hours and a +0.40% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.523 pivot point. If it approaches the $0.4583 support level, significant changes may occur.
Previous Close:
$0.5251
Open:
$0.508
24h Volume:
26,288
Market Cap:
$3.96M
Revenue:
$5.18M
Net Income/Loss:
$-7.79M
P/E Ratio:
-0.20
EPS:
-2.36
Net Cash Flow:
$-4.99M
1W Performance:
-15.73%
1M Performance:
+0.40%
6M Performance:
-60.34%
1Y Performance:
-71.05%
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858 345 1494
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
Oct-19-17 | Resumed | FBR & Co. | Buy |
Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
Jul-19-16 | Reiterated | FBR Capital | Outperform |
Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
Mar-16-16 | Initiated | Northland Capital | Outperform |
Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
Feb-17-16 | Resumed | FBR Capital | Outperform |
Dec-03-14 | Reiterated | MLV & Co | Buy |
Nov-07-14 | Initiated | MLV & Co | Buy |
Apr-22-14 | Initiated | Laidlaw | Buy |
Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma (NASDAQ:EVOK) Stock Price Passes Below 200 Day Moving Average of $0.72 - Defense World
Defense World
VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com - Defense World
Defense World
United Natural Foods (NYSE:UNFI) Raised to “Hold” at StockNews.com - Defense World
Defense World
Rave Restaurant Group (NASDAQ:RAVE) Now Covered by StockNews.com - Defense World
Defense World
Park City Group (NASDAQ:PCYG) Now Covered by StockNews.com - Defense World
Defense World
Sotherly Hotels (NASDAQ:SOHO) Now Covered by Analysts at StockNews.com - Defense World
Defense World
Evoke Pharma Inc Stock (EVOK) Financials Data
Evoke Pharma Inc (EVOK) Revenue 2024
EVOK reported a revenue (TTM) of $5.18 million for the quarter ending December 31, 2023, a +106.51% rise year-over-year.
Evoke Pharma Inc (EVOK) Net Income 2024
EVOK net income (TTM) was -$7.79 million for the quarter ending December 31, 2023, a +5.25% increase year-over-year.
Evoke Pharma Inc (EVOK) Cash Flow 2024
EVOK recorded a free cash flow (TTM) of -$4.99 million for the quarter ending December 31, 2023, a +24.42% increase year-over-year.
Evoke Pharma Inc (EVOK) Earnings per Share 2024
EVOK earnings per share (TTM) was -$2.33 for the quarter ending December 31, 2023, a +11.74% growth year-over-year.
About Evoke Pharma Inc
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Cap:
|
Volume (24h):